PULSE the living trend engine
🤖 Open Intelligence Dossier available for AI agents & citation View Markdown (.md) →
◼ Archived Business 🔮 PULSE predicts: fades by tomorrow — graded ✓ correct

EyePoint Stock Craters 69% After Drug Trial Failure. It May Be an Overreaction.

2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

2sources
2articles
1velocity
+0%since first seen
67d agofirst detected

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

The brief

"EyePoint Stock Craters 69% After Drug Trial Failure. It May Be an Overreaction." is generating significant coverage in the Business category, with 2 articles from 2 distinct sources tracked by PULSE so far.

Outlets currently covering the story include The Boston Globe and BioPharma Dive. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.

This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.

Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 65d ago.

Quick answers

Why is "EyePoint Stock Craters 69% After Drug Trial Failure. It May Be an Overreaction." trending?

Because 2 independent news sources published 2 articles about it in a short window — a coverage burst PULSE classifies as a trend.

How does PULSE measure this trend?

PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.

Is this trend still active?

The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.

Coverage (2)

Topics

EyePoint Stock Craters After Drug

Related trends

\n \n \n \n \n \n \n